| payload |
{"created_at":"2026-04-03T11:12:58.166 {"created_at":"2026-04-03T11:12:58.166696+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:36810c4aca7e4441","evidence_event_ids":["evt_121f3b16bd8a"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1347178/0001628280-26-023222.txt","as_of":"2026-04-03T11:12:58.166696+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1347178/0001628280-26-023222.txt","company":"Vanda Pharmaceuticals Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1347178/0001628280-26-023222.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_a94f82df1d83aba4","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1347178/0001628280-26-023222.txt","content_type":"text/plain","enriched_at":"2026-04-03T13:52:47.723369+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"vnda-20260329","final_url":"https://www.sec.gov/Archives/edgar/data/1347178/0001628280-26-023222.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1347178/0001628280-26-023222.txt","source_event_id":"evt_121f3b16bd8a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"e5d200a8dd135d07","kind":"sec_filing","published_at":"20260402","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-03-29","2026-04-02","2026-04-10"],"entities":[{"asset_class":"equity","name":"Vanda Pharmaceuticals Inc.","relevance":"high","symbol":"VNDA","type":"company"}],"event_type":"other","information_gaps":["No details provided on the reasons for Timothy Williams' resignation."],"key_facts":["Timothy Williams notified the company of his resignation on March 29, 2026.","The resignation is effective as of April 10, 2026."],"numeric_claims":[],"primary_claim":"Timothy Williams resigned from his position at Vanda Pharmaceuticals Inc., effective April 10, 2026.","relevance_score":0.7,"sentiment":"neutral","source_quality":"high","summary":"Vanda Pharmaceuticals Inc. filed an 8-K report disclosing the resignation of Timothy Williams as Senior Vice President, General Counsel, and Secretary, effective April 10, 2026.","topics":["SEC Filing","Executive Resignation"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Vanda Pharmaceuticals Inc. \u00b7 Filed 20260402","ticker":"VNDA","tickers":["VNDA"],"title":"VNDA filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1347178/0001628280-26-023222.txt"}}... |